Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | ELANE | P08246 | 11/20 | 0.37 |
| ▸ | CTSB | P07858 | 2/20 | 0.36 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16318497 | 1.00 | CYP3A4 (0.55) | CYP3A4ELANECTSBPPP3CBIRAK4 | |
| SCHEMBL16318495 | 1.00 | CYP3A4 (0.55) | CYP3A4ELANECTSBPPP3CBIRAK4 | |
| SCHEMBL16318585 | 0.90 | CYP3A4 (0.49) | CYP3A4ELANECTSBPPP3CBIRAK4 | |
| SCHEMBL15213305 | 0.90 | CYP3A4 (0.49) | CYP3A4ELANECTSBPPP3CBIRAK4 | |
| SCHEMBL16318584 | 0.90 | CYP3A4 (0.49) | CYP3A4ELANECTSBPPP3CBIRAK4 | |
| SCHEMBL16318484 | 0.87 | CYP3A4 (0.41) | CYP3A4CTSBIRAK4 | |
| SCHEMBL16318483 | 0.87 | CYP3A4 (0.41) | CYP3A4CTSBIRAK4 | |
| SCHEMBL3375479 | 0.86 | CYP3A4 (0.65) | CYP3A4ELANECTSB | |
| SCHEMBL1074488 | 0.81 | CYP3A4 (0.40) | CYP3A4IRAK4 | |
| SCHEMBL1074490 | 0.81 | CYP3A4 (0.40) | CYP3A4IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321809-B2 | Macrocyclic compounds for suppressing replication of hepatitis C virus | GINKGO PHARAMA CO., LTD. (CN) | 2016-04-26 | — | — | US | disclosed |
| US-9321809-B2 | Macrocyclic compounds for suppressing replication of hepatitis C virus | GINKGO PHARAMA CO., LTD. (CN) | 2016-04-26 | — | — | US | disclosed |
| US-20150031603-A1 | MACROCYCLIC COMPOUNDS FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS | GINKGO PHARMA CO., LTD. (CN) | 2015-01-29 | — | — | US | disclosed |
| US-20150031603-A1 | MACROCYCLIC COMPOUNDS FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS | GINKGO PHARMA CO., LTD. (CN) | 2015-01-29 | — | — | US | disclosed |
| EP-2816054-A1 | MACROCYCLIC COMPOUNDS FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS | GINKGO PHARMA CO., LTD. (CN) | 2014-12-24 | — | — | EP | disclosed |
| EP-2816054-A1 | MACROCYCLIC COMPOUNDS FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS | GINKGO PHARMA CO., LTD. (CN) | 2014-12-24 | — | — | EP | disclosed |
| WO-2013120371-A1 | MACROCYCLIC COMPOUNDS FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS | 银杏树药业(苏州)有限公司 (CN) | 2013-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031603-A1 | MACROCYCLIC COMPOUNDS FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS | HCCS, HAVCR2, EIF2AK2 | CYP3A4 469/4885ELANE 641/4885CTSB 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.